Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis
Crossref DOI link: https://doi.org/10.1007/s10549-016-4064-9
Published Online: 2016-11-24
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wang, Ruo-Xi
Chen, Sheng
Jin, Xi
Chen, Can-Ming
Shao, Zhi-Ming
License valid from 2016-11-24